# Economic Wrap

#### October 2020

## Summary

* Market performance was mixed during October as developed markets including the US struggled.

##### 1. S&P/ASX 200 Price Index



Source: Bloomberg, IOOF

##### 2. ASX200 vs All-World, US$ terms



Source: Bloomberg, IOOF

##### 3. Australia – Growth vs Value stocks



Source: Bloomberg, IOOF

##### 4. Emerging markets vs Developed Markets, (In USD)



Sources: Bloomberg, MSCI, S&P, IOOF

* Coronavirus case growth accelerated especially in Europe and also in the USA. Both regions are seeing hospitalisations and fatalities on the rise, but these remain below prior peaks.
* The surge in cases has prompted new lockdown measures across Europe of varying levels of severity. We believe a measured approach will prevail with Germany an example of this.
* Joe Biden, the Democrat nominee has defeated incumbent President Trump in the US Presidential Election. Results in the Congressional races were tighter with a Republican Senate a likely outcome that would stifle Biden’s legislative agenda.
* Promising vaccine trial results by a Pfizer joint-venture in November triggered dispersion in financial markets on the prospects of a viable solution to the pandemic and stronger economic growth.

## Markets

* Risk assets including equities and high-yield bonds were broadly positive however coronavirus fears weighed on global equity markets (see page 11).
* Australian equities outperformed vs global peers (see chart 2) while value stocks continued to falter (see chart 3). Emerging market strength has become more pronounced in recent months (see chart 4) after a strong month for Chinese equities, bolstered by the prospect of a Biden win and strong economic data.

## Key economic news

* The 2021 Australian Federal Budget targeted a business-led recovery from the recession caused by coronavirus lockdowns.
* The RBA launched a new series of measures to promote growth and weaken the Australian dollar.

## Key company news

Acquisition interest saw strong returns for Coca Cola Amatil, the target of a bid by Coca Cola European Partners while Link Administration Holdings also saw takeover interest with bidding by a Pacific Equity Partners and Carlyle Group consortium of investors. Mesoblast shares struggled after its disclosure that the US FDA had not approved its remestemcel-L treatment for paediatric patients dealing with steroid-refractory acute graft versus host disease (SR-aGVHD) with a class action by shareholders also weighing on the business.

## Sector and stock returns

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| ASX/S&P 200 Sectors (GICS) | | | | |
|  | Monthly | % ∆ | Quarterly | % ∆ |
| ▲ | Consumer Discretionary | 1.33 | Consumer Discretionary | 6.32 |
| ▲ | Consumer Staples | 4.75 | Consumer Staples | -3.57 |
| ▼ | Energy | -0.84 | Energy | -9.96 |
| ▲ | Financials ex Property | 6.27 | Financials ex Property | 0.07 |
| ▲ | Financials | 6.27 | Financials | 0.07 |
| ▲ | Health Care | 1.17 | Health Care | 5.60 |
| ▼ | Industrials | -3.92 | Industrials | -0.45 |
| ▲ | IT | 8.96 | IT | 16.91 |
| ▼ | Materials | -1.23 | Materials | -4.62 |
| ▼ | Property Trusts | -0.37 | Property Trusts | 5.60 |
| ▼ | Telecommunications | -0.55 | Telecommunications | -7.98 |
| ▼ | Utilities | -1.49 | Utilities | -10.70 |

Source: Bloomberg, IOOF

|  |  |  |  |
| --- | --- | --- | --- |
| Best and Worst S&P/ASX 200 Performers | | | |
| Top five stocks | | Bottom five stocks | |
| Monthly | | | |
| Coca-Cola Amatil Ltd | +30.8% | Mesoblast Ltd | -39.8% |
| Link Administration Holdings | +27.9% | Flight Centre Travel Group Ltd | -18.2% |
| Virgin Money UK Plc – CDI | +26.6% | Austal Ltd | -17.4% |
| Challenger Ltd | +25.6% | Regis Resources Ltd | -17.2% |
| Sims Ltd | +25.5% | Megaport Ltd | -16.3% |
| Quarterly | | | |
| Corporate Travel Group | +72.2% | Resolute Mining | -55.5% |
| ARB Corporation | +60.3% | IOOF Holdings Ltd | -54.7% |
| Nine Entertainment Co. Holdings Ltd | +53.5% | Bravura Solutions | -52.7% |
| Reliance Worldwide | +53.4% | The a2 Milk Company | -51.7% |
| Coca-Cola Amatil | +52.0% | Gold Road Resources Ltd | -48.0% |

Source: Bloomberg, IOOF

## Share Markets, October 2020

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Australian Indices | | Oct-20 Price | 1M return (%) | Jul-20 Price | 3M return (%) |
| ▲ | S&P/ASX 200 | 5928 | 1.92 | 5928 | 0.00 |
| ▲ | All Ordinaries | 6133 | 2.06 | 6058 | 1.24 |
| ▲ | Small Ordinaries | 2736 | 0.34 | 2634 | 3.90 |
| US Indices | | | | | |
| ▼ | S&P 500 | 3270 | -2.77 | 3271 | -0.04 |
| ▼ | Dow Jones | 26502 | -4.61 | 26428 | 0.28 |
| ▼ | Nasdaq | 10912 | -2.29 | 10745 | 1.55 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Asia Pacific Indices | | | | | |
| ▲ | Hang Seng | 24107 | 2.76 | 24595 | -1.98 |
| ▼ | Nikkei 225 | 22977 | -0.90 | 21710 | 5.84 |
| UK & Europe Indices | | | | | |
| ▼ | FTSE 100 | 5577 | -4.92 | 5898 | -5.43 |
| ▼ | CAC40 | 4594 | -4.36 | 4784 | -3.96 |
| ▼ | DAX Index | 11556 | -9.44 | 12313 | -6.15 |

Sources: Bloomberg, MSCI, FTSE, S&P, IOOF

Note: return is reported on a price basis and in local currency terms

e.g. S&P500 performance is in US dollars and excluding dividends

### Global equity markets

Chinese equities were a notable source of strength during October with the Hang Seng Index one of the few in positive territory. Emerging markets more broadly benefited from expectations of more stable trade relations under a Biden presidency.

For developed markets price action was driven by:

* increased concerns over escalation in coronavirus cases in both Europe and the US. New lockdown restrictions with businesses consequently forced to shut down weighed especially on European indices with the German DAX Index falling 9.4%.
* In the US uncertainty over the presidential election and a lack of progress on further fiscal stimulus weighed on the market.



Source: Bloomberg, IOOF, MSCI

At a style level, October showed some signs of a rotation-trade away from Momentum and Quality towards both value and small caps which showed strong relative outperformance especially the latter. Stronger economic growth expectations in the US were a factor following positive economic data. This weakened the duration trade that had arguably benefitted growth stock valuations. Given US dominance in global and growth-style indices, this drove overall benchmark returns lower.

### Australian equity markets

The Australian market defied trends in global equities with a 1.9% rise for the benchmark S&P/ASX 200 Price Index. At a sector level, the benchmark was driven higher by the banking (up 6.3%) and technology sectors (up 9.0%). The Budget was well-received as a sign that the Coalition was committed to support the economy. This supported bank stocks in anticipation of an earlier economic recovery.



Source: Bloomberg, IOOF, MSCI

At a style level, Australia differed slightly to global share markets. Small caps underperformed in October, but this view needs to acknowledge the outperformance they enjoyed since the March lows with smaller Australian companies rerating faster than global peers. Australian small caps beat large caps in the year to October in contrast to the global trend.

Geopolitical risks also reappeared following month-end in stocks with exposure to Chinese exports such as Treasury Wine Estates. The wine producer, maker of brands such as Penfolds, saw itself the subject of anti-dumping investigation by Chinese authorities with potential tariff hikes as a result. It remains unclear how much these measures are legitimate as opposed to punishment over strained Australian-Chinese relations regarding Hong Kong and Chinese handling of the coronavirus pandemic. The result is a net negative regardless. More crucial exports, particularly iron ore have remained unaffected to date.

## Fixed Income

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Fixed Income | | Oct-20 yield | 1M mvt (bps) | Jul-20 yield | 3M mvt (bps) |
|  | Australian Cash rate | 0.25 | -- | 0.25 | -- |
| ▲ | 10-year Bond Yield | 0.83 | 0.04 | 0.82 | 0.01 |
| ▼ | 3-year Bond Yield | 0.12 | -0.04 | 0.27 | -0.15 |
| ▼ | 90 Day Bank Bill yield | 0.06 | -0.03 | 0.11 | -0.05 |
| ▲ | US 10-year Bond Yield | 0.87 | 0.19 | 0.53 | 0.35 |
| ▲ | US 3-year Bond Yield | 0.20 | 0.04 | 0.11 | 0.08 |
| ▼ | US Investment Grade spread | 1.41 | -0.11 | 1.46 | -0.05 |
| ▼ | US High Yield spread | 4.91 | -0.17 | 4.84 | 0.07 |

Source: Bloomberg, IOOF

### Australian bond market

The Australian yield curve steepened slightly during October but was largely unchanged across most of the term structure (different years of maturity).

##### 5. Australian yield curve changes to October 2020



This reflected increased speculation of another RBA rate cut which was subsequently delivered on 3 November, leaving the cash rate at 0.10%. In addition, the RBA announced additional bond purchases to the tune of $100bn in a bid to lower longer-term borrowing costs and separately purchases would be made to maintain its (now) lower target for the 3-year bond yield of 0.1%.

Who wins from the latest RBA changes?

* State and Federal governments will gain from lower borrowing costs which will support the sizeable budget deficits in the years ahead.
* Borrowers benefit, to the extent that banks, pass on lower mortgage rates (this has mainly been done by changing fixed rate offers).
* Australian exporters should benefit, is the theory, from a lower Australian dollar as the RBA policy removes bonds and adds dollars from markets while the rate cut makes our dollar less attractive to speculators (because they now earn a lower interest rate on it).

As noted in prior updates, these moves exacerbate the pain for savers with shorter-term cash accounts and even some term deposits offering negative real (after-inflation) interest rates.

### US bond market

US Treasury yields rose during October particularly for longer-dated bonds. This reflected strong US economic data with solid labour market reports and continued strength in the manufacturing sector despite a rise in coronavirus cases as the country headed into winter (when economic growth is typically weaker).

##### 6. US yield curve movement to October 2020



US credit spreads fell during the month in contrast with the weakness seen in equity markets. This reflects continued improvement in economic data notwithstanding additional coronavirus cases with less concern over corporate bankruptcy risk by investors.

We expect the surge in coronavirus cases to weigh on both the growth and inflation outlook in the near term, supporting bond returns. However new developments on the vaccine front by a Pfizer joint venture suggest we could be closer to the end of the pandemic. Further news flow here has the potential to trigger a violent market reaction as it did on 9 November.

## Currencies

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Currencies | | Oct-20 Price | 1M return (%) | Jul-20 Price | 3M return (%) |
| ▼ | $A vs $US | 70.28 | -1.87 | 71.43 | -1.61 |
| ▼ | $A vs GBP | 54.27 | -2.11 | 54.59 | -0.59 |
| ▼ | $A vs YEN | 73.56 | -2.63 | 75.59 | -2.68 |
| ▼ | $A vs EUR | 60.35 | -1.24 | 60.65 | -0.49 |
| ▼ | $A vs $NZ | 106.25 | -1.86 | 107.75 | -1.39 |
| ▼ | $A TWI | 59.50 | -1.98 | 61.90 | -3.88 |
| ▲ | $US vs EUR | 85.86 | 0.63 | 84.90 | 1.13 |
| ▼ | $US vs CNY | 6.69 | -1.46 | 6.98 | -4.07 |
| ▼ | $US vs GBP | 77.22 | -0.21 | 76.42 | 1.05 |
| ▼ | $US vs JPY | 104.66 | -0.78 | 105.83 | -1.11 |
| ▼ | $US vs CHF | 91.70 | -0.42 | 91.29 | 0.45 |
| ▲ | US Dollar Index | 94.04 | 0.16 | 93.35 | 0.74 |
| ▼ | EM Currency Index | 54.29 | -0.42 | 55.60 | -2.36 |

Source: Bloomberg, IOOF

The Australian dollar (AUD) fell 1.9% against the US Dollar (USD) during October, from USD 0.7162 to USD 0.7028. Drivers included:

* Growth in coronavirus cases in developed markets such as Europe and the US triggered a shift to “risk off” sentiment in currency markets. Such changes adversely affect the Australian dollar which, due to our commodity export exposure, is seen as leveraged on global economic growth. Weaker global growth expectations, all else being equal, weakens our currency.
* Another factor was the extent that the market had “priced in” expectations of RBA policy prior to their announcement in early November. Speculation was rife amongst market observers over what the RBA would do exactly with their policies broadly in line with market consensus.

Conversely the US Dollar was supported by a flight to safety which saw the DXY index rise. Separately we note since month-end with both the vaccine news and Biden election victory, a stronger global growth scenario was expected prompting a month-to-date surge in the AUD of 3% (as of 12 November).

## Commodities

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Commodities | | Oct-20 Price | 1M return (%) | Jul-20 Price | 3M return (%) |
| ▲ | Aluminium | 1854 | 5.78 | 1713 | 8.23 |
| ▲ | Copper | 305 | 0.49 | 289 | 5.43 |
| ▲ | Nickel | 15128 | 4.32 | 13797 | 9.65 |
| ▲ | Zinc | 2515 | 4.93 | 2322 | 8.35 |
| ▼ | Crude Oil - Brent | 37.5 | -8.52 | 43.30 | -13.49 |
| ▲ | Natural Gas | 3.35 | 32.73 | 1.80 | 86.44 |
| ▼ | Coking Coal | 129 | -1.07 | 130 | -1.07 |
| ▲ | Thermal Coal | 60 | 4.00 | 51 | 19.26 |
| ▼ | Iron Ore | 120.2 | -3.06 | 108.9 | 10.37 |
| ▼ | Gold | 1880 | -0.82 | 1986 | -5.34 |
| ▲ | Silver | 24 | 0.65 | 24 | -3.36 |

Source: Bloomberg, IOOF

**Oil** prices weakened substantially in October driven by expectations of tighter lockdown restrictions in Europe. Some of these had already begun in October for smaller countries such as Ireland. New lockdown measures restrict people’s mobility lowering demand for automotive fuel and crimp what had been a nascent recovery in travel, lowering jet fuel usage. A faster-than-expected return to production from Libyan fields also pressured prices by increasing oil supply.

**Natural Gas** (an important Australian export) prices surged. This continued their recovery from March and was driven by ongoing speculation over weaker US production with US firms cutting capital spending and on track for production substantially below Winter 2019/20 levels.

**Precious metals** specifically gold struggled against a stronger real yield (bond yield after inflation) environment following rising US bond yields.

**Aluminium prices** continued to be supported by demand from China and resilience in global manufacturing with the Markit Global Aluminium Users PMI now at 55.6, its highest since Dec-10. **Iron ore prices** were also supported by Chinese demand, with the Markit Steel PMI also at its highest since Dec-10.

## Australia

The FY21 Federal Budget was well-received with consumer and business confidence recovering strongly. RBA policy measures will be supportive of the necessary deficit spending at a State and Federal level while stronger volumes suggest the retail environment (and consumer spending) remain favourable even with the drag of Victorian lockdowns. As noted by the RBA, it likely the economy exited recession with positive growth during the September quarter.

### Policy

As mentioned earlier the RBA has cut the cash rate by 0.15% to a record low of 0.1% in line with our remarks for the September quarterly. This move also coincided with a lowering of its target for 3-year government bond yields over the next few years with a return to higher rates only expected with a materially tighter labour market (i.e. unemployment below 5%) and sustained inflation in its target band, an outcome we are some years from realising.

The Jobseeker payment at a lower rate of $715 per fortnight has been extended until March 2021. Initially the coronavirus supplement payment was $550, currently $250 and will fall to $150 for the March quarter. This is supportive for the economy as it supports consumers with a higher tendency to spend.

### Business sector

Business sentiment and activity improved into October. According to the NAB Monthly Business Survey, confidence rose to 5 points, its highest since mid-2019 with business conditions entered positive territory for the first time in several months. Further increases in trading and profitability drove the business conditions higher as Victoria exiting lockdown restrictions served as a notable tailwind. However, the employment index continues to suggest pressure on jobs growth in the near term. As noted in our previous update, capacity utilisation below its pre-Covid or long-term average levels suggests the investment spending boom the government was hoping for may take more time to be realised (if it ultimately occurs).

**Growth outlook**

The Westpac-Melbourne Institute Leading Index rose to -0.48% in September, up from -2.28% in August. Stronger US industrial production, rising hours worked domestically and improvements in consumer confidence were all notable drivers of this recovery. It is expected to improve further in the months ahead following recent stimulus announcements with the bringing forward of personal income tax cuts expected to support consumer spending in Westpac’s view.

**Inflation**

Headline inflation rose 1.6% in the September quarter or 0.7% for the year to September. This was a notable recovery from the deflation in the June quarter which had been driven by lockdown restrictions and the temporary government offer of free childcare.

Results from the NAB Monthly Business Survey suggest subdued inflationary pressures from businesses while wage inflation is also subdued given the backdrop of higher unemployment.

**Retail sales**

Retail sales for the September quarter showed a marked recovery as consumer spending, supported by stimulus, rose strongly following the lifting of lockdown restrictions. On a volume basis, retail turnover rose 6.5% for the quarter and 4.2% for the year to September. This came against a backdrop of a second wave of cases within Victoria and the need for a severe lockdown particularly in Melbourne. Strong levels of consumer confidence noted in our last update should support consumer spending as will the lifting of Victorian restrictions.

**Coronavirus pandemic**

Containment of coronavirus cases continued to improve domestically during October and into November. NSW has seen 6 consecutive days of no locally transmitted cases and Victoria 14 consecutive days of no new cases or deaths, a material improvement from the situation in the September quarter. Border restrictions are also being lifted with all States and Territories excluding Western Australia agreeing to reopen their borders to internal travel by Christmas. The government has also announced a prioritisation of the elderly and other vulnerable groups once a coronavirus vaccine becomes more widely available. The focus now is on gradual normalisation of internal economic activity which we expect to continue seeing and acting as an economic tailwind in the months ahead.

## United States

Democrat nominee Joe Biden was elected as the 46th President of the United States with incumbent President Trump refusing to concede amidst legal and other challenges to the outcome. The coronavirus pandemic has continued to grow in the US and begun to see lockdown restrictions reappear while economic data has remained broadly positive.

**US Elections**

On 3 November we saw races for both the Presidency and US Congress. Joe Biden appears likely to have exceeded the 270 Electoral College votes needed to win the election. Races in North Carolina and Georgia remain unclear, but Biden may expand his total votes to over 300 when the voting is finalised. President Trump is contesting the outcome, but we believe the margin of Biden’s lead in several close States is large enough that a recount will not materially change the outcome while allegations of electoral fraud remain unsubstantiated.

The Democrats have retained control of the US House of Representatives and may still claim the Senate depending on the outcome in Georgia. There the votes were sufficiently close to trigger runoff elections on 5 January 2021 for both Senate seats. If the Democrats were to win both they would be able to control both the Presidency and Congress.

Without Senate control a Biden Presidency would be limited in its ability to deliver campaign promises, assuming a Republican Senate is unwilling to negotiate (as it was in the later years of the Obama Presidency). He will still be able, however, to promote better diplomatic relations relative to President Trump’s unilateral trade actions and trade war saga. He would also via appointments to key Federal agencies be able to promote a stronger environmental protection agenda and potentially tougher corporate regulation. It remains unclear exactly if or when President Trump will concede the defeat.

**Coronavirus outbreak**

In chart 7 we can see a sharp rise in US coronavirus cases and coronavirus deaths since bottoming around 13 September. This case growth has been led by States such as Illinois and Texas. This has prompted at a State-level the introduction of new restrictions to limit public gatherings and in some cases quarantine internal travel.

##### 7. US coronavirus case and fatality growth



Thankfully the new escalation has not been met with a matching rise in fatalities at present with levels highlighted in Chart 7 still well below the earlier phase of the pandemic in April. However, per chart 8 below we can see hospitalisations for coronavirus rising to a new peak. This suggests that fatalities will continue rising in the near term but also that levels are not so extended to overwhelm the healthcare system at present. There is potential for more Federal leadership with a Biden Administration outlining key steps such as wider mask usage that should, if implemented help contain the pandemic sooner.

##### 8. US coronavirus current hospitalisations



**Growth and growth outlook**

The US economy grew at an annualised 33.1% pace in the September quarter (consensus: 32%). A surge in both business and residential investment and stronger household spending supported by government stimulus were key drivers of the result. This came even following the expiration of the *CARES Act* stimulus payments.

Leading indicators including the Conference Board Leading Economic Index and the ECRI Weekly Leading Index suggest growth momentum should continue improving in the near term. The Weekly Economic Index from the NY Fed suggesting the December quarter should show a continued uptick in growth. In addition, the Markit Composite PMI rose to 56.3 in October, up from 54.3 in September, a 29-month high. Even amidst the pandemic both manufacturing and services activity improved although the rise in coronavirus infections may slow or even arrest this momentum in the near term..

## China

The Chinese economic recovery has continued this year with further expansion recorded for the September quarter. Business surveys suggest continued improvement into October although geopolitical risks in Hong Kong and trade remain a feature, clouding the outlook potentially.

### Economic growth

The Chinese economy grew 4.9% in the year to September, slightly below expectations (consensus: 5.2%). The recovery was business-led with services a point of weakness only growing 0.4% for the first three quarters of the year in contrast to 2.3% for the agriculture and resources sector and 0.9% for the manufacturing sector. Retail sales continued to struggle with only a 0.9% rise during the September quarter. There are signs of a gradual recovery in employment which should boost consumption spending and there are some positive signs with tech firms Alibaba and JD seeing a combined $115bn in sales on Single’s Day (an annual sales event in China) and Alibaba more than doubling its total sales over that period (sales here referring to transactions on the platform rather than revenue to the firm itself).

### Business activity and sentiment

Chinese economic activity continued to strengthen at the start of the fourth quarter with the Composite PMI rising from 54.5 in September to 55.7 in October. This was supported by strength across both the manufacturing and services sectors with new business expanding and job growth also improving, a marked change from the contraction seen earlier in the year. The overall composite output was the second highest in a decade while new business made a decade-high and business expectations also continued to strengthen as in previous updates the domestic situation stood in contrast to that of overseas demand. The acceleration in new coronavirus cases in Europe and the US saw the new business gauge for the services sector remain in contractionary territory but domestic strength helped to offset this impact.

### Inflation

Inflationary pressures remained subdued in the year to October with consumer inflation tracking at 0.5% growth (down from 1.7% in September) and producer inflation unchanged at 2.1% for the year to October. The drop in consumer inflation was heavily influenced by the improving pork supply after disease drove sizeable price inflation at the beginning of the year. The core inflation rate (stripping out volatile price effects) was unchanged at 0.5% with inflation remaining well below the 3.5% target that was set for 2020 by authorities.

As with other countries, deflationary pressures remain the more pressing concern compared to rising inflation.

### Geopolitics

In Hong Kong the legislature passed a new law that, amongst other features, saw several members of the democratic Opposition lose the seats. This move has sparked international outcry with the UK reportedly planning sanctions against China whilst Australian authorities have also condemned the action. We also saw President Trump sign a new Executive Order forbidding US firms from investing in firms owned or substantially controlled by the Chinese military.

The month was also marked by increased speculation of further punitive measures against Australian exports using a mix of investigations and outright bans. The lack of substantiated reasoning suggests a punitive component to the exercise, one unlikely to end until Chinese authorities deem Australia sufficiently punished. Australian authorities have steered clear of any direct countermeasures, preferring instead to weather the damage in the near term, likely a reflection of China’s greater importance to Australian resource and agricultural exports.

**Trade balance**

Chinese exports grew 11.4% in the year to October (consensus: 9.3%) driving the trade surplus for the month to $58.44bn (consensus: $46bn). Strong demand for medical supplies and challenges to manufacturing elsewhere amidst the pandemic have supported sales of Chinese manufactured goods. Imports rose 4.7% over the same period (consensus: 9.5% increase), a second straight month of growth but lagging expectations. While this is supportive of the Chinese recovery, we note that this may lead to trade becoming a contentious issue given China is benefitting more from other countries’ stimulus efforts. US. Much will depend on the stance of the incoming Biden Administration with campaign promises suggesting it will not be an “easy” path for China necessarily.

## Europe

An acceleration of coronavirus infections prompted tighter lockdown restrictions across Europe, beginning in October and escalating further in November. These raise the risk of a negative growth quarter to end 2020. Brexit negotiations remain inconclusive and pose another near-term risk to the regional outlook.

**United Kingdom**

The UK saw an extension of its wage-subsidisation scheme for furloughed workers until March 2021with support also being extended to self-employed workers from November until January 2021.

It comes as the UK entered a second national lockdown (due to end in early December) as coronavirus case growth soared during October and November. As many as 2 million jobs were still being protected by the existing scheme in mid-October with the Bank of England estimating that as many as 5.5 million people could be added following the November extension. The new UK lockdown restrictions resemble those we saw in Australia earlier this year with non-essential services including restaurants closed and a general direction to remain home unless necessary for education or work reasons. One difference is that schools and universities have remained open (a process replicated in Continental Europe as well).

Lastly, we note that Brexit negotiations have remained inconclusive even as the 31 December deadline is rapidly approaching. Difficult sticking points on both sides including fishery access and state subsidies are amongst the main sticking points.

A lack of a finalised deal will compound the difficult economic situation of the region and appears to be growing more likely unless as has occurred in the past, some last-minute pragmatism emerges.

**Coronavirus pandemic**

October and, subsequently November saw a pronounced surge in both cases and fatalities in Europe with deaths rapidly approaching the April peak (unlike the US experience). This triggered widespread lockdowns across the continent albeit less severe than we saw during April. While it remains early as we can see in Chart 9, case growth while elevated has begun to flatline with some countries still seeing an increase whilst others such as France are now seeing case growth decline. Lockdowns will eventually halt further case growth but in the meantime, they will materially detract from economic activity, raising the risk of another contraction in European growth.

##### 9. Eurozone coronavirus current hospitalisations



An earlier-than-expected vaccine such as the success of the recent Pfizer joint venture solution in medical trials would be a welcome boost for Europe especially as it grapples with the impact of the pandemic.

**Eurozone growth**

The Eurozone economy grew by 12.1% in the September quarter (-3.9% for the year to September) according to Eurostat. Strength in France, Italy and Spain was key to driving the overall regional result. The impact of new restrictions particularly on Southern Europe which is more reliant on tourism exports is expected to be substantial. As noted above there is a reasonable chance of another quarter of negative growth in December.

**Policy**

The European Central Bank is expected to introduce additional monetary stimulus in December with a mix of cheaper bank funding and additional bond purchases likely tools. As discussed in prior updates there are limitations in how much these policies can realistically achieve given the already low borrowing costs prevailing across Europe.

Another concern is the progress on the fiscal policy front. There are some divisions that still need to be reconciled. The European Recovery Fund is intended to offer a mix of grants (money not needing to be repaid) and loans (money that would be repaid) to EU members. Remarks by ECB Board member Yves Mersch suggested the ECB should act to prevent governments’ avoiding the use of the loans by withdrawing its support in bond purchase programs. This is not official policy, but it points to a potential repeat of past mistakes where European governments engaged in austerity early and contributed to a second recession after the financial crisis.

## Company news - best and worst performers during October 2020

### Coca Cola Amatil (+30.8%)

Coca-Cola Amatil (CCA) received a takeover from its European counterpart Coca-Cola European Partners (CCEP) for $12.75 per share, valuing the company at $9bn, and propping up the share price toward the end of the month. The deal is set to provide CCEP further growth opportunities outside its core European market while also providing geographic diversification. The deal which has the blessing of the board and CCA’s majority shareholder, The Coca-Cola Company (TCCC), has already agreed to sell CCEP it’s 30.8% stake in CCA, however several shareholders (Pendal, Martin Currie, and Antares) oppose the takeover, saying the deal is opportunistic and undervalues CCA’s post-pandemic potential.

### Link Administration Holdings (+27.9%)

Link Administration Holdings (LNK) received a joint takeover bid by private equity groups, The Carlyle Group and Pacific Equity Partners, for $5.20 per share which valued the company at $3.8bn. The deal places significant value on LNK’s 44% holding of PEXA, an e-conveyancing software with a market leading position in the fast-growing market for electronic settlement of property. The offer was subsequently rejected by the board with subsequent talks of an IPO of PEXA as a possibility for LNK to realise its investment in the software.

### Virgin Money UK (+26.6%)

Virgin Money UK (VUK) is undergoing an aggressive cost cutting and integration program with 400 jobs set to be cut as part of a plan to reduce its workforce by 16% to increase efficiencies within the bank. The former NAB subsidiary, Clydesdale Bank, rebranded Virgin Money UK after a successful takeover by Virgin Money, is set to continue to undergo a period of restructuring as its new owner seeks to produce an estimated £200m in cost savings by 2022 and turn around the underperforming bank.

### Mesoblast (-39.8%)

Mesoblast (MSB) reported a disappointing October after the FDA unexpectedly rejected MSBs Ryoncil Remestemcel-L and demanded further randomised controlled studies in adults and children to provide more evidence of effectiveness. The news came as a shock to the market which was expecting a smooth approval process given that the FDA Oncologic Drugs Advisory Committee (ODAC) voted 9-1 in favour of the drug’s efficacy given existing data. Although MSBs treatment could still get Ryoncil approved within 3-6 months under an accelerated approval process, the setback produced a high level of uncertainty around the future of the drug.

### Flight Centre (-18.2%)

Flight Centre (FLT) continued its slide downwards as a resurgent second wave took hold in Europe and the Americas, dampening hopes for a fast recovery in airline travel. The announcement of a pause in Oxford-AstraZeneca’s Phase III trial due to an unknown sickness produced in one of its participants and the cancellation of a “trans-Tasman” travel bubble before Christmas also added pressure on FLTs share price.

### Austal (-17.4%)

Austral Boats (ASB) was caught up in a corruption investigation after the Australian Border Force (ABF) was alleged to have improperly funnelled $39m from a national security project to ASB to prop up its financial position. The allegations state that ASB was improperly paid out $39m that was part of a contingent “success” fee on the condition that it delivered patrol boats (used for targeting contraband smugglers and illegal fishing) with no mechanical problems, which were not met but paid after intense lobbying. The investigation is currently ongoing.

**Sources:** ASX company announcements, Bloomberg, Fund manager disclosures, Australian Financial Review, Sydney Morning Herald

## Movers and Shakers for month of October 2020

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ASX  Code | Company Name | Closing  price ($) | | Month ago,  close ($) | Month  price  return (%) | Quarter ago  close ($) | Quarter  Price return  (%) | Year ago,  close ($) | Annual Price Return  (%) |
| CCL | Coca-Cola Amatil Ltd | | 12.43 | 9.50 | 30.8 | 8.18 | 52.0 | 10.15 | 22.5 |
| LNK | Link Administration Holdings | | 4.77 | 3.73 | 27.9 | 3.98 | 19.8 | 5.60 | -14.8 |
| VUK | Virgin Money UK Plc – CDI | | 1.64 | 1.30 | 26.6 | 1.63 | 0.9 | 2.59 | -36.7 |
| CGF | Challenger Ltd | | 4.81 | 3.83 | 25.6 | 4.34 | 10.8 | 7.96 | -39.6 |
| SGM | Sims Ltd | | 9.51 | 7.58 | 25.5 | 7.95 | 19.6 | 9.35 | 1.7 |
| LYC | Lynas Corp Ltd | | 2.83 | 2.32 | 22.0 | 2.20 | 28.7 | 2.45 | 15.7 |
| APT | Afterpay Ltd | | 96.69 | 79.99 | 20.9 | 68.54 | 41.1 | 28.86 | 235.0 |
| URW | Unibail-Rodamco-Westfield | | 2.90 | 2.42 | 19.8 | 3.62 | -19.9 | 11.10 | -73.9 |
| PME | Pro Medicus Ltd | | 32.39 | 27.07 | 19.7 | 23.92 | 35.4 | 26.66 | 21.5 |
| NEC | Nine Entertainment Co Hldgs | | 2.08 | 1.75 | 19.2 | 1.36 | 53.5 | 1.84 | 13.0 |

Source: Bloomberg, IOOF

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| ASX  Code | Company Name | Closing  price ($) | Month ago,  close ($) | Month  price  return (%) | Quarter ago  close ($) | Quarter  Price return  (%) | Year ago,  close ($) | Annual Price Return  (%) |
| MSB | Mesoblast Ltd | 3.06 | 5.08 | -39.8 | 3.78 | -19.0 | 1.79 | 71.4 |
| FLT | Flight Centre Travel Grp Ltd | 11.26 | 13.77 | -18.2 | 10.59 | 6.3 | 38.34 | -70.6 |
| ASB | Austal Ltd | 2.71 | 3.28 | -17.4 | 3.30 | -17.9 | 4.18 | -35.2 |
| RRL | Regis Resources Ltd | 4.15 | 5.01 | -17.2 | 5.63 | -26.3 | 4.90 | -15.3 |
| MP1 | Megaport Ltd | 13.47 | 16.09 | -16.3 | 13.15 | 2.4 | 9.28 | 45.2 |
| CTD | Corporate Travel Management | 14.60 | 17.23 | -15.3 | 8.48 | 72.2 | 17.13 | -14.7 |
| AVH | Avita Therapeutics Inc CDI | 5.93 | 6.90 | -14.1 | 6.07 | -2.3 | 11.90 | -50.2 |
| RSG | Resolute Mining Ltd | 0.80 | 0.93 | -14.0 | 1.30 | -38.5 | 1.21 | -33.9 |
| BVS | Bravura Solutions Ltd | 2.93 | 3.40 | -13.8 | 4.18 | -29.9 | 4.11 | -28.7 |
| OBL | Omni Bridgeway Ltd | 3.45 | 3.93 | -12.2 | 4.58 | -24.7 | 3.41 | 1.2 |

Source: Bloomberg, IOOF

## Long-term asset class performance to October 2020 (Total returns in AUD)

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | | | | Annualised | | | | | | |
| Asset class | 1-mth | 3-mth | 6-mth | 1-yr | 3-yr | 5-yr | 7-yr | 10-yr | 15-yr | 20-yr |
| Australian equities (S&P/ASX 200) | **1.9%** | **1.0%** | **8.7%** | **-8.1%** | **4.1%** | **6.8%** | **5.6%** | **6.9%** | **6.4%** | **7.5%** |
| Australian equities - Mid caps | **6.1%** | **9.3%** | **25.2%** | **8.9%** | **8.2%** | **11.8%** | **11.9%** | **9.8%** | **7.5%** | **10.5%** |
| Australian equities - Small caps | **0.5%** | **4.7%** | **15.1%** | **-2.4%** | **4.6%** | **8.6%** | **5.9%** | **3.2%** | **3.8%** | **5.7%** |
| Australian equities - Micro caps | **1.3%** | **15.0%** | **41.5%** | **6.4%** | **8.3%** | **10.6%** | **6.6%** | **1.4%** | **4.3%** | **#N/A** |
| International equities | **-1.1%** | **2.0%** | **4.9%** | **2.7%** | **9.2%** | **8.5%** | **12.1%** | **12.5%** | **7.0%** | **3.3%** |
| International equities (Hedged) | **-3.2%** | **-0.3%** | **10.4%** | **1.1%** | **4.9%** | **8.0%** | **9.0%** | **11.0%** | **7.9%** | **#N/A** |
| International equities - Small caps | **2.1%** | **5.3%** | **9.7%** | **-1.9%** | **4.8%** | **7.1%** | **10.5%** | **12.0%** | **7.4%** | **6.5%** |
| Emerging Markets equities | **4.2%** | **4.8%** | **12.8%** | **6.2%** | **5.0%** | **8.3%** | **7.9%** | **5.9%** | **6.9%** | **#N/A** |
| Australian REITs | **-0.4%** | **5.9%** | **12.4%** | **-18.0%** | **2.8%** | **4.5%** | **8.0%** | **9.6%** | **3.4%** | **6.3%** |
| Global REITs | **-1.3%** | **-1.9%** | **-5.4%** | **-24.4%** | **0.5%** | **0.5%** | **6.2%** | **7.5%** | **4.2%** | **#N/A** |
| Global REITs (Hedged) | **-3.4%** | **-4.0%** | **-0.5%** | **-25.5%** | **-3.2%** | **0.0%** | **3.3%** | **6.0%** | **4.5%** | **#N/A** |
| Global Infrastructure | **1.4%** | **0.5%** | **-3.6%** | **-11.4%** | **5.0%** | **6.0%** | **10.0%** | **10.9%** | **#N/A** | **#N/A** |
| Global Infrastructure (Hedged) | **-0.6%** | **-1.2%** | **1.4%** | **-10.8%** | **1.9%** | **5.8%** | **7.4%** | **9.9%** | **#N/A** | **#N/A** |
| Trend following (USD) | **-1.5%** | **-4.2%** | **-5.3%** | **-1.4%** | **-0.6%** | **-2.0%** | **2.1%** | **0.4%** | **3.3%** | **5.4%** |
| Australian bonds | **0.3%** | **0.9%** | **1.9%** | **4.0%** | **5.7%** | **4.5%** | **5.1%** | **5.6%** | **5.8%** | **6.0%** |
| Australian bonds - government | **0.2%** | **0.9%** | **1.7%** | **4.0%** | **5.9%** | **4.6%** | **5.2%** | **5.6%** | **5.8%** | **5.9%** |
| Australian bonds – corporate | **0.6%** | **1.2%** | **3.6%** | **4.3%** | **5.3%** | **4.8%** | **5.1%** | **5.9%** | **6.1%** | **6.2%** |
| Australian bonds - floating rate | **0.3%** | **0.4%** | **1.4%** | **1.9%** | **2.4%** | **2.8%** | **2.9%** | **3.7%** | **4.3%** | **4.7%** |
| Global bonds (Hedged) | **0.0%** | **-0.4%** | **1.4%** | **3.8%** | **4.5%** | **4.4%** | **5.0%** | **5.7%** | **6.5%** | **7.0%** |
| Global bonds - government (Hedged) | **-0.1%** | **-0.4%** | **0.4%** | **3.6%** | **4.7%** | **4.3%** | **5.1%** | **5.7%** | **6.4%** | **6.9%** |
| Global bonds - corporate (Hedged) | **0.1%** | **-0.7%** | **4.8%** | **4.7%** | **5.0%** | **5.5%** | **5.7%** | **6.6%** | **6.9%** | **7.5%** |
| Global bonds - High Yield (Hedged) | **0.2%** | **0.0%** | **10.7%** | **-0.3%** | **1.9%** | **5.5%** | **5.4%** | **7.5%** | **8.5%** | **#N/A** |
| Emerging Market bonds (Hedged) | **0.0%** | **-1.7%** | **12.2%** | **-0.6%** | **2.3%** | **5.3%** | **5.5%** | **6.4%** | **7.9%** | **10.0%** |
| Cash (AUD) | **0.0%** | **0.0%** | **0.1%** | **0.5%** | **1.4%** | **1.6%** | **1.9%** | **2.5%** | **3.6%** | **4.0%** |

**Sources:** Bloomberg, IOOF calculations

\* AUD total returns as at Oct-20 assuming reinvestment of dividends unless otherwise specified

\*\* Returns reflect index performance excluding any fees; Actual ETF/managed fund performance will vary due to both fees and tracking error.

## Appendix – Index sources

|  |  |
| --- | --- |
| Asset class | Index |
| Australian equities (S&P/ASX 200) | S&P/ASX 200 Accumulation Index |
| Australian equities - Mid caps | S&P/ASX Accumulation Midcap 50 Index |
| Australian equities - Small caps | S&P/ASX Accumulation Small Cap Ordinaries Index |
| Australian equities - Micro caps | S&P/ASX Emerging Companies Total Return Index |
| International equities | MSCI World ex Australia Net Total Return (in AUD) |
| International equities (Hedged) | MSCI World ex Australia Hedged AUD Net Total Return Index |
| International equities - Small caps | MSCI World Small Cap Net Total Return USD Index (in AUD) |
| Emerging Markets equities | MSCI Emerging Markets EM Net Total Return AUD Index |
| Australian REITs | S&P/ASX 200 A-REIT Accumulation Index |
| Global REITs | FTSE EPRA/NAREIT Developed Index Net Total Return (in AUD) |
| Global REITs (Hedged) | FTSE EPRA/NAREIT Developed Index Net Total Return (Hedged to AUD) |
| Global Infrastructure | FTSE Global Core Infrastructure 50/50 Net Total Return in AUD |
| Global Infrastructure (Hedged) | FTSE Global Core Infrastructure 50/50 100% Hedged to AUD Net Tax Index |
| Trend following | SGI Cross Asset Trend Following Index (USD) |
| Australian bonds | Bloomberg AusBond Composite 0+ Yr Index |
| Australian bonds - government | Bloomberg AusBond Govt 0+ Yr Index |
| Australian bonds – corporate | Bloomberg AusBond Credit 0+ Yr Index |
| Australian bonds - floating rate | Bloomberg AusBond Credit FRN 0+ Yr Index |
| Global bonds (Hedged) | Bloomberg Barclays Global Aggregate Total Return Index Value Hedged AUD |
| Global bonds - government (Hedged) | Bloomberg Barclays Global Aggregate Treasuries Total Return Index Hedged AUD |
| Global bonds - corporate (Hedged) | Bloomberg Barclays Global Aggregate Corporate Total Return Index Hedged AUD |
| Global bonds - High Yield (Hedged) | Bloomberg Barclays Global High Yield Total Return Index Hedged AUD |
| Emerging Market bonds (Hedged) | J.P. Morgan EMBI Global Core Hedged Index Level AUD |
| Cash (AUD) | Bloomberg AusBond Bank Bill Index |

Research Analyst – Cameron Curko

Approved By – Matt Olsen

**Research Analyst Disclosures:**

I, Cameron Curko, hereby certify that all the views expressed in this report accurately reflect my personal views about the subject investment theme and/or company securities. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

I, Cameron Curko, and/or entities in which I have a pecuniary interest, have an exposure to the following securities and/or managed products mentioned in this report: Nil

**Important Information**

This report is prepared by Bridges Financial Services Pty Limited ABN 60 003 474 977 AFSL 240837 (Bridges). Bridges is an ASX Market Participant and part of the IOOF group of companies. This report is prepared by the IOOF Research team for:

Bridges Financial Services Pty Limited ABN 60 003 474 977 AFSL 240837, Consultum Financial Advisers Pty Ltd ABN 65 006 373 995 AFSL 230323, Elders Financial Planning ABN 48 007 997 186 AFSL 224645, Financial Services Partners ABN 15 089 512 587 AFSL 237 590, Millennium3 Financial Services Pty Ltd ABN 61 094 529 987 AFSL 244252, RI Advice Group Pty Ltd ABN 23 001 774 125 AFSL 238429, Shadforth Financial Group Ltd ABN 27 127 508 472 AFSL 318613 (‘Advice Licensees’). The Advice Licensees are part of the IOOF group comprising IOOF Holdings ABN 49 100 103 722 and its related bodies corporate (IOOF group).

The Advice Licensees and/or their associated entities, directors and/or employees may have a material interest in, and may earn brokerage from, any securities or other financial products referred to in this document, or may provide services to the company referred to in this report. The document is not available for distribution outside Australia and may not be passed on to any third person without the prior written consent of the Advice Licensees. The Advice Licensees and associated persons (including persons from whom information in this report is sourced) may do business or seek to do business with companies covered in its research reports. As a result, investors should be aware that the firms or other such persons may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as a single factor in making an investment decision.

The document is current as at the date of issue but may be superseded by future publications. You can confirm the currency of this document by checking the intranet site (links below).

The information contained in this report is for the sole use of advisers and clients of AFSL entities authorised by the Advice Licensees. This report may be used on the express condition that you have obtained a copy of the Advice Licensees Financial Services Guide (FSG) from their respective website.

Disclaimer: The information in this report is general advice only and does not take into account the financial circumstances, needs and objectives of any particular investor. Before acting on the advice contained in this document, you should assess your own circumstances or seek advice from a financial adviser. Where applicable, you should obtain and consider a copy of the Product Disclosure Statement, prospectus or other disclosure material relevant to the financial product before making a decision to acquire a financial product. It is important to note that investments may go up and down and past performance is not an indicator of future performance.

The contents of this report should not be disclosed, in whole or in part, to any other party without the prior consent of the IOOF Research Team and Advice Licensees. To the extent permitted by the law, the IOOF Research team and Advice Licensees and their associated entities are not liable for any loss or damage arising from, or in relation to, the contents of this report.

For information regarding any potential conflicts of interest and analyst holdings; IOOF Research Team’s coverage criteria, methodology and spread of ratings; and summary information about the qualifications and experience of the IOOF Research Team please visit https://www.ioof.com.au/adviser/investment\_funds/ioof\_advice\_research\_process